FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Monte Rosa Therapeutics, Inc. Stock AnalysisComprehensive stock analysis for Monte Rosa Therapeutics, Inc. (GLUE) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisGLUE
GLUE
Monte Rosa Therapeutics, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
GLUE
Home🔹Stocks🔹Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc.

GLUE•NASDAQ

Monte Rosa Therapeutics, Inc.

GLUE•NASDAQ
Market cap
$1.86B
Sentiment

Your view on GLUE

Mkt Cap
$1.86B
Sentiment
Your view
GLUE
Monte Rosa Therapeutics, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
GLUE
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Monte Rosa Therapeutics, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Markus Warmuth
Headquarters
645 Summer Street, Boston, MA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Markus Warmuth
Headquarters
645 Summer Street, Boston, MA, US
Description

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News